Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir

被引:91
作者
Hurt, AC
Barr, IG
Hartel, G
Hampson, AW
机构
[1] WHO, Collaborating Ctr Reference & Res Influenza, Parkville, Vic 3052, Australia
[2] CSL Ltd, Parkville, Vic, Australia
关键词
influenza; neuraminidase inhibitors; oseltamivir carboxylate; zanamivir;
D O I
10.1016/j.antiviral.2003.11.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human influenza viruses isolated from Australasia (Australia and New Zealand) and South East Asia were analysed to determine their sensitivity to the NA inhibitor drugs, zanamivir and oseltamivir. A total of 532 strains isolated between 1998 and 2002 were tested using a fluorescence-based assay to measure the relative inhibition of NA activity over a range of drug concentrations. Based on median IC50 values, influenza A viruses (with neuraminidase subtypes N1 and N2) were more sensitive to both the NA inhibitors than were influenza B strains. Influenza A viruses with a N1 subtype and influenza B strains both demonstrated a greater sensitivity to zanamivir than to oseltamivir carboxylate, whereas influenza A strains with a N2 subtype were more susceptible to oseltamivir carboxylate. For each of the neuraminidase types, IC50 values for viruses from Australasia and South East Asia were found to be comparable. Based on the data prior to and following the licensing of the drugs into the respective regions, the use of the NA inhibitors did not appear to have a significant impact on the susceptibility of the viruses tested to zanamivir or oseltamivir carboxylate. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:37 / 45
页数:9
相关论文
共 26 条
[1]   Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies [J].
Barnett, JM ;
Cadman, A ;
Gor, D ;
Dempsey, M ;
Walters, M ;
Candlin, A ;
Tisdale, M ;
Morley, PJ ;
Owens, IJ ;
Fenton, RJ ;
Lewis, AP ;
Claas, ECJ ;
Rimmelzwaan, GF ;
De Groot, R ;
Osterhaus, ADME .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (01) :78-87
[2]   GENETIC-BASIS OF RESISTANCE TO RIMANTADINE EMERGING DURING TREATMENT OF INFLUENZA-VIRUS INFECTION [J].
BELSHE, RB ;
SMITH, MH ;
HALL, CB ;
BETTS, R ;
HAY, AJ .
JOURNAL OF VIROLOGY, 1988, 62 (05) :1508-1512
[3]   Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors [J].
Boivin, G ;
Goyette, N .
ANTIVIRAL RESEARCH, 2002, 54 (03) :143-147
[4]   Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus [J].
Gubareva, LV ;
Matrosovich, MN ;
Brenner, MK ;
Bethell, RC ;
Webster, RG .
JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (05) :1257-1262
[5]   Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en [J].
Gubareva, LV ;
Robinson, MJ ;
Bethell, RC ;
Webster, RG .
JOURNAL OF VIROLOGY, 1997, 71 (05) :3385-3390
[6]   Influenza virus neuraminidase inhibitors [J].
Gubareva, LV ;
Kaiser, L ;
Hayden, FG .
LANCET, 2000, 355 (9206) :827-835
[7]  
Hay A.J., 1992, SEMIN VIROL, V3, P21, DOI DOI 10.1016/J.BMC.2015.06.030
[8]  
HAYDEN FG, 1996, ANTIVIRAL DRUG RESIS, P78
[9]  
Ison Michael G., 2001, Current Opinion in Pharmacology, V1, P482, DOI 10.1016/S1471-4892(01)00084-4
[10]   Management of influenza - Use of new antivirals and resistance in perspective [J].
Jackson, HC ;
Roberts, N ;
Wang, ZM ;
Belshe, R .
CLINICAL DRUG INVESTIGATION, 2000, 20 (06) :447-454